Brian Ray Campbell

US Patent:

7087601, Aug 8, 2006

Filed:

Nov 26, 2002

Appl. No.:

10/497452

Inventors:

Jeannie Arruda - San Diego CA, US
Celine Bonnefous - San Diego CA, US
Brian T. Campbell - San Diego CA, US
Rowena V. Cube - San Diego CA, US
Benito Munoz - San Diego CA, US
Brian Stearns - San Diego CA, US
Jean-Michel Vernier - San Diego CA, US
Bowei Wang - San Diego CA, US
Xiumin Zhao - San Diego CA, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 31/5383
A61K 31/437
C07D 413/14
C07D 491/048

US Classification:

5142342, 514302, 544127, 546115

Abstract:

Phenyl compounds substituted at the 1-position with a fused bicyclo moeity formed from a five-membered heterocycle fused to a six-membered carbocycle, to a six-membered aryl, or to a six-membered hetaryl, and further optionally substituted at the 3,4 positions, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, and panic, as well as in the treatment of pain and other diseases.

US Patent:

7105533, Sep 12, 2006

Filed:

Sep 9, 2003

Appl. No.:

10/527044

Inventors:

Brian Thomas Campbell - San Diego CA, US
Janet Lorraine Gunzer - Berkeley CA, US
Benito Munoz - San Diego CA, US
Brian Andrew Stearns - San Diego CA, US
Jean-Michel Andre Vernier - San Diego CA, US
Bowei Wang - San Diego CA, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 31/4375
A61K 31/4439
C07D 471/02
C07D 487/02
C07D 513/02

US Classification:

514299, 514300, 514338, 546112, 546119, 546121, 5462687, 5462701

Abstract:

Phenyl compounds substituted with a fused-heterobicyclo moiety, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, and panic, as well as in the treatment of pain and other diseases.

US Patent:

7465730, Dec 16, 2008

Filed:

Jul 8, 2003

Appl. No.:

10/520962

Inventors:

Naomi Burke Anker - Boston MA, US
Jeannie M. Arruda - San Diego CA, US
Brian Thomas Campbell - San Diego CA, US
Benito Munoz - San Diego CA, US
Petpiboon Prasit - San Diego CA, US
Brian A. Stearns - San Diego CA, US
Tao Hu - San Diego CA, US

Assignee:

Merck & Co. Inc. - Rahway NJ

International Classification:

A01N 43/58
A61K 31/5025
C07D 487/06

US Classification:

514252, 544236

Abstract:

6H-pyrrolo[3,4-d]pyridazine compounds and methods of their use of as ligands of voltage gated calcium channels (VGCC), useful in the treatment of neuropathic pain, and psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, panic, and bipolar disorder, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm disorders, drug addiction, drug abuse, drug withdrawal and other.

US Patent:

7910561, Mar 22, 2011

Filed:

Dec 9, 2005

Appl. No.:

11/792121

Inventors:

Jeannie M. Arruda - San Diego CA, US
Brian T. Campbell - San Diego CA, US
Nicholas D. P. Cosford - San Diego CA, US
Jacob M. Hoffman - Lansdale PA, US
Essa H. Hu - Camarillo CA, US
Mark E. Layton - Harleysville PA, US
Yiwei Li - Ambler PA, US
Jun Liang - Palo Alto CA, US
Kevin J. Rodzinak - Schwenksville PA, US
Tony Siu - Brookline MA, US
Brian A. Stearns - San Diego CA, US
Lida R. Tehrani - San Diego CA, US
Mark T. Bilodeau - Lansdale PA, US
Peter J. Manley - Harleysville PA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A01N 43/04
A01N 43/58
A01N 43/42
A61K 31/541
A61K 31/70
A61K 31/50
A61K 31/495
A61K 31/52
C09B 25/00
C07D 487/00
C07D 491/00
C07H 15/00

US Classification:

514 43, 51421021, 514249, 51426322, 514314, 536 292, 544277, 544350, 546173

Abstract:

The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention. These substituted naphthyridines have unexpected advantageous properties when compared to other naphthyridines reported in PCT publication WO2003/086394, such unexpected advantageous properties may include increased cellular potency/solubility, greater selectivity, enhanced pharmacokinetic properties, lack of off target activity and so on.

US Patent:

8618289, Dec 31, 2013

Filed:

Mar 17, 2009

Appl. No.:

12/933402

Inventors:

Sunny Abraham - San Diego CA, US
Shripad S. Bhagwat - San Diego CA, US
Brian T. Campbell - Burlington NJ, US
Qi Chao - San Diego CA, US
Raffaella Faraoni - San Diego CA, US
Mark W. Holladay - San Diego CA, US
Andiliy G. Lai - San Diego CA, US
Martin W. Rowbottom - San Diego CA, US
Eduardo Setti - San Mateo CA, US
Kelly G. Sprankle - Vista CA, US

Assignee:

Ambit Biosciences Corporation - San Diego CA

International Classification:

C07D 239/70
A01N 43/54

US Classification:

544253, 5142581

Abstract:

Compounds according to formula (I), compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases. Formula (I): or a pharmaceutically acceptable salt, solvate, clathrate of hydrate thereof, wherein X is O or S(O); Ris O or S.

US Patent:

20140045868, Feb 13, 2014

Filed:

Oct 8, 2013

Appl. No.:

14/048655

Inventors:

SHRIPAD S. BHAGWAT - SAN DIEGO CA, US
BRIAN T. CAMPBELL - BURLINGTON NJ, US
QI CHAO - SAN DIEGO CA, US
RAFFAELLA FARAONI - SAN DIEGO CA, US
MARK W. HOLLADAY - SAN DIEGO CA, US
ANDILIY G. LAI - SAN DIEGO CA, US
MARTIN W. ROWBOTTOM - SAN DIEGO CA, US
EDUARDO SETTI - SAN MATEO CA, US
KELLY G. SPRANKLE - VISTA CA, US

Assignee:

AMBIT BIOSCIENCES CORPORATION - SAN DIEGO CA

International Classification:

C07D 413/12

US Classification:

5142662, 544284

Abstract:

Compounds, compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases.

US Patent:

20170298029, Oct 19, 2017

Filed:

Jun 28, 2017

Appl. No.:

15/636562

Inventors:

- San Diego CA, US
Shripad S. BHAGWAT - San Diego CA, US
Brian T. CAMPBELL - Burlington NJ, US
Qi CHAO - San Diego CA, US
Raffaella FARAONI - San Diego CA, US
Mark W. HOLLADAY - San Diego CA, US
Andiliy G. LAI - San Diego CA, US
Martin W. ROWBOTTOM - San Diego CA, US
Eduardo SETTI - San Mateo CA, US
Kelly G. SPRANKLE - Vista CA, US

Assignee:

AMBIT BIOSCIENCES CORPORATION - San Diego CA

International Classification:

C07D 239/88
C07D 261/14

Abstract:

Compounds, compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases.

US Patent:

20160199375, Jul 14, 2016

Filed:

Mar 18, 2016

Appl. No.:

15/074671

Inventors:

- San Diego CA, US
Shripad S. Bhagwat - San Diego CA, US
Brian T. Campbell - Burlington NJ, US
Qi Chao - San Diego CA, US
Raffaella Faraoni - San Diego CA, US
Mark W. Holladay - San Diego CA, US
Andiliy G. Lai - San Diego CA, US
Martin W. Rowbottom - San Diego CA, US
Eduardo Setti - San Mateo CA, US
Kelly G. Sprankle - Vista CA, US

International Classification:

A61K 31/517
A61K 9/48
A61K 9/20

Abstract:

Compounds, compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases.